FI930195A - Biarylsubstituerade 4-aminosmoersyraamider - Google Patents

Biarylsubstituerade 4-aminosmoersyraamider Download PDF

Info

Publication number
FI930195A
FI930195A FI930195A FI930195A FI930195A FI 930195 A FI930195 A FI 930195A FI 930195 A FI930195 A FI 930195A FI 930195 A FI930195 A FI 930195A FI 930195 A FI930195 A FI 930195A
Authority
FI
Finland
Prior art keywords
aminosmoersyramider
biaryl
substitutes
biaryl substitutes
Prior art date
Application number
FI930195A
Other languages
English (en)
Other versions
FI930195A0 (fi
Inventor
Gary Ksander
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of FI930195A0 publication Critical patent/FI930195A0/fi
Publication of FI930195A publication Critical patent/FI930195A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/12—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI930195A 1992-01-22 1993-01-18 Biarylsubstituerade 4-aminosmoersyraamider FI930195A (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/824,132 US5217996A (en) 1992-01-22 1992-01-22 Biaryl substituted 4-amino-butyric acid amides

Publications (2)

Publication Number Publication Date
FI930195A0 FI930195A0 (fi) 1993-01-18
FI930195A true FI930195A (fi) 1993-07-23

Family

ID=25240671

Family Applications (1)

Application Number Title Priority Date Filing Date
FI930195A FI930195A (fi) 1992-01-22 1993-01-18 Biarylsubstituerade 4-aminosmoersyraamider

Country Status (14)

Country Link
US (2) US5217996A (fi)
EP (1) EP0555175A1 (fi)
JP (1) JPH05310664A (fi)
KR (1) KR930016393A (fi)
AU (1) AU666902B2 (fi)
CA (1) CA2087652A1 (fi)
FI (1) FI930195A (fi)
HU (1) HUT63376A (fi)
IL (1) IL104387A0 (fi)
MX (1) MX9300310A (fi)
NO (1) NO930193L (fi)
NZ (1) NZ245716A (fi)
TW (1) TW228513B (fi)
ZA (1) ZA93421B (fi)

Families Citing this family (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides
IL115995A0 (en) * 1994-11-15 1996-01-31 Bayer Ag Substituted 4-biarylbutyric or 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors
TR199700834T1 (xx) * 1995-02-22 1998-01-21 Novartis Ag 1-Aril-2-Akilamino ethan bile�ikleri ve bunlar�n n�rokinin olarak �zellikle n�rokinin 1 has�mlar� olarak kullan�mlar�.
MY132550A (en) 1996-08-22 2007-10-31 Novartis Ag Acylaminoalkenylene-amide derivatives as nk1 and nk2 antogonists
IL144285A0 (en) * 1999-03-29 2002-05-23 Bristol Myers Squibb Co Pharmaceutical compositions containing a vasopeptidase inhibitor
US7468390B2 (en) * 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
CN1615134A (zh) * 2002-01-17 2005-05-11 诺瓦提斯公司 含有缬沙坦和nep抑制剂的药物组合物
GB0203061D0 (en) * 2002-02-08 2002-03-27 Novartis Ag Organic compounds
ATE550656T1 (de) * 2003-08-20 2012-04-15 Alere San Diego Inc Verfahren und zusammensetzungen zur messung biologisch aktiver natriuretischer peptide und zur verbesserung ihres therapeutischen potentials
US7868037B2 (en) * 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7781478B2 (en) * 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) * 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US8013006B2 (en) * 2004-07-14 2011-09-06 Ptc Therapeutics, Inc. Methods for treating hepatitis C
MX2007000762A (es) 2004-07-22 2007-04-02 Ptc Therapeutics Inc Tienopiridinas para tratamientode hepatitis c.
MY146830A (en) * 2005-02-11 2012-09-28 Novartis Ag Combination of organic compounds
WO2007045663A2 (en) * 2005-10-19 2007-04-26 Novartis Ag Combination of an ati receptor antagonist and a np inhibitor fro treating ia hypertension and heartfailure
RU2459809C2 (ru) * 2005-11-09 2012-08-27 Новартис Аг Фармацевтические комбинации антагониста рецептора ангиотензина и ингибитора nep
AR057882A1 (es) * 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
EP1903027A1 (en) * 2006-09-13 2008-03-26 Novartis AG Process for preparing biaryl substituted 4-amino-butyric acid or derivatives thereof and their use in the production of NEP inhibitors
JP5715339B2 (ja) * 2007-01-12 2015-05-07 ノバルティス アーゲー ５−ビフェニル−４−アミノ−２−メチルペンタン酸の製造方法
TW200838501A (en) 2007-02-02 2008-10-01 Theravance Inc Dual-acting antihypertensive agents
TWI448284B (zh) * 2007-04-24 2014-08-11 Theravance Inc 雙效抗高血壓劑
TWI406850B (zh) 2007-06-05 2013-09-01 Theravance Inc 雙效苯并咪唑抗高血壓劑
EP2200975A1 (en) 2007-09-07 2010-06-30 Theravance, Inc. Dual-acting antihypertensive agents
AU2008307798B2 (en) * 2007-10-05 2013-10-03 Verastem, Inc. Pyrimidine substituted purine derivatives
US8212052B2 (en) * 2007-12-11 2012-07-03 Theravance, Inc. Dual-acting benzoimidazole antihypertensive agents
AU2012202949B2 (en) * 2008-01-17 2015-01-22 Novartis Ag Process and intermediates for the preparation of 5-biphenyl-4-yl-2-methylpentanoic acid derivatives
PE20091364A1 (es) * 2008-01-17 2009-10-13 Novartis Ag Proceso para la preparacion de inhibidores de nep
JP2011518884A (ja) 2008-04-29 2011-06-30 セラヴァンス， インコーポレーテッド 二重活性抗高血圧剤
CN101607875B (zh) * 2008-06-17 2012-07-25 中国石油化学工业开发股份有限公司 制造环烷酮的方法
EP2334651A2 (en) 2008-07-24 2011-06-22 Theravance, Inc. Dual-acting antihypertensive agents
CN101774941A (zh) * 2009-01-13 2010-07-14 浙江九洲药业股份有限公司 2-酰基氨基-3-联苯基丙酸的制备及拆分方法
EP2434895A4 (en) 2009-05-13 2013-08-07 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
ME01923B (me) * 2009-05-28 2015-05-20 Novartis Ag Supstituisani derivati aminopropionske kiseline kao inhibitori neprilizina
MX2011012627A (es) * 2009-05-28 2011-12-14 Novartis Ag Derivados aminobutiricos sustituidos como inhibidores de nepralisina.
ES2611107T3 (es) 2009-07-07 2017-05-04 Theravance Biopharma R&D Ip, Llc Agentes antihipertensivos de pirazol, de doble acción
WO2011011232A1 (en) 2009-07-22 2011-01-27 Theravance, Inc. Dual-acting oxazole antihypertensive agents
JO2967B1 (en) 2009-11-20 2016-03-15 نوفارتس ايه جي Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
US8481549B2 (en) 2010-01-19 2013-07-09 Theravance, Inc. Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
ES2550485T3 (es) * 2010-01-22 2015-11-10 Novartis Ag Intermedios de inhibidores de la endopeptidasa neutra y método de preparación de los mismos
PL2609075T3 (pl) 2010-08-23 2016-09-30 Sposób wytwarzania związków pośrednich do produkcji inhibitorów NEP
CN103080072B (zh) 2010-08-23 2016-03-16 诺华有限公司 制备可用于生产nep抑制剂的中间体的新方法
MA34483B1 (fr) 2010-08-24 2013-08-01 Novartis Ag Traitement de l'hypertension et/ou prévention ou traitement de l'insuffisance cardiaque l'insuffisance cardiaque chez un mammifère recevant une therapie anticoagulante
US8993631B2 (en) * 2010-11-16 2015-03-31 Novartis Ag Method of treating contrast-induced nephropathy
US8673974B2 (en) 2010-11-16 2014-03-18 Novartis Ag Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
ME02295B (me) 2010-12-15 2016-02-20 Theravance Biopharma R&D Ip Llc Inhibitori neprilizina
MX354476B (es) 2010-12-15 2018-03-07 Theravance Inc Inhibidores de neprilisina.
EP2675792B1 (en) 2011-02-17 2016-01-06 Theravance Biopharma R&D IP, LLC Substituted aminobutyric derivatives as neprilysin inhibitors
WO2012112742A1 (en) 2011-02-17 2012-08-23 Theravance, Inc. Substituted aminobutyric derivatives as neprilysin inhibitors
CA2835220A1 (en) 2011-05-31 2012-12-06 Theravance, Inc. Neprilysin inhibitors
CN103596928B (zh) 2011-05-31 2017-02-15 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
ES2642883T3 (es) 2011-05-31 2017-11-20 Theravance Biopharma R&D Ip, Llc Inhibidores de neprilisina
TWI560172B (en) 2011-11-02 2016-12-01 Theravance Biopharma R&D Ip Llc Neprilysin inhibitors
AR089955A1 (es) * 2012-02-15 2014-10-01 Theravance Inc Proceso para preparar compuestos de acido 4-amino-5-bifenil-4-il-2-hidroximetil-2-metil-pentanoico
CA2871292A1 (en) 2012-05-31 2013-12-05 Theravance Biopharma R&D Ip, Llc Nitric oxide donor neprilysin inhibitors
PL2864292T3 (pl) 2012-06-08 2017-10-31 Theravance Biopharma R&D Ip Llc Inhibitory neprylizyny
CN104470521B (zh) 2012-06-08 2017-04-12 施万生物制药研发Ip有限责任公司 脑啡肽酶抑制剂
RS55797B1 (sr) 2012-08-08 2017-08-31 Theravance Biopharma R&D Ip Llc Inhibitori neprilizina
WO2014029848A1 (en) 2012-08-24 2014-02-27 Novartis Ag Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling
TR201808541T4 (tr) 2013-02-14 2018-07-23 Novartis Ag Nep (nötr endopeptidaz) inhibitörleri olarak ikame edilmiş bisfenil butanoik fosfonik asit türevleri.
MX2015010434A (es) 2013-02-14 2015-10-05 Novartis Ag Derivados de acido bisfenil-butanoico sustituido como inhibidores de la endopeptidasa neutra (nep), con una mayor eficacia in vivo.
JP6549040B2 (ja) 2013-02-17 2019-07-24 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規使用
US8901169B2 (en) 2013-03-05 2014-12-02 Theravance Biopharma R&D Ip, Llc Neprilysin inhibitors
CN104230865B (zh) * 2013-06-13 2018-01-09 上海翰森生物医药科技有限公司 联芳基取代的4‑氨基丁酸衍生物及其制备方法和用途
WO2015028941A1 (en) 2013-08-26 2015-03-05 Novartis Ag New use
EP3038653A1 (en) 2013-08-26 2016-07-06 Novartis AG New use
WO2015116760A1 (en) 2014-01-30 2015-08-06 Theravance Biopharma R&D Ip, Llc 5-biphenyl-4-heteroarylcarbonylamino-pentanoic acid derivatives as neprilysin inhibitors
US9593110B2 (en) 2014-01-30 2017-03-14 Theravence Biopharma R&D IP, LLC Neprilysin inhibitors
CN106795099B (zh) * 2014-04-10 2019-11-26 南京奥昭生物科技有限公司 用于治疗高血压和心血管疾病的前药和组合物
JP6591530B2 (ja) 2014-08-07 2019-10-16 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
CN105461587A (zh) * 2014-08-27 2016-04-06 上海翰森生物医药科技有限公司 Ahu-377半钙盐晶型及其制备方法和应用
CN105622452A (zh) * 2014-08-27 2016-06-01 上海翰森生物医药科技有限公司 Ahu-377结晶型游离酸及其制备方法和应用
CN105367438A (zh) * 2014-08-27 2016-03-02 上海翰森生物医药科技有限公司 AHU-377α-苯乙胺盐多晶型及其制备方法和应用
WO2016029828A1 (zh) * 2014-08-27 2016-03-03 上海翰森生物医药科技有限公司 AHU-377结晶型游离酸、半钙盐、α﹣苯乙胺盐及其制备方法和应用
WO2016037098A1 (en) 2014-09-04 2016-03-10 Concert Pharmaceuticals, Inc. Deuterated sacubitril
PL3218351T3 (pl) 2014-11-14 2019-12-31 Zentiva K.S. Sposób wytwarzania, wyodrębniania i oczyszczania farmaceutycznie dopuszczalnych postaci AHU-377
CN105693543B (zh) * 2014-12-15 2018-08-10 四川海思科制药有限公司 沙库比曲类衍生物、其药物组合物、制备方法及用途
CN104557600B (zh) * 2015-01-26 2016-05-04 苏州明锐医药科技有限公司 沙库比曲的制备方法
MY187899A (en) 2015-02-11 2021-10-27 Theravance Biopharma R&D Ip Llc (2s,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-4-(ethoxyoxalylamino)-2-hydroxymethyl-2-methylpentanoic acid as neprilysin inhibitor
TW201632493A (zh) 2015-02-13 2016-09-16 諾華公司 新穎方法
MY191183A (en) 2015-02-19 2022-06-04 Theravance Biopharma R&D Ip Llc (2r,4r)-5-(5'-chloro-2'-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid
WO2016135751A1 (en) 2015-02-25 2016-09-01 Mylan Laboratories Limited Novel process for the preparation of sacubitril and its intermediates
CN105963296B (zh) * 2015-03-12 2020-01-21 深圳信立泰药业股份有限公司 一种含有阿利沙坦酯或其盐或其水解产物或其水解产物盐的药物组合物及其用途
AU2016236659B9 (en) * 2015-03-20 2019-05-02 Crystal Pharmatech Co., Ltd. AHU377 crystal form, preparation method and use thereof
PT3294283T (pt) 2015-05-11 2023-06-07 Novartis Ag Regime de dosagem de sacubitril-valsartan para tratar a insuficiência cardíaca
WO2016193883A1 (en) 2015-05-29 2016-12-08 Novartis Ag Sacubitril and valsartan for treating metabolic disease
CN104860894B (zh) * 2015-06-10 2017-05-17 北京博全健医药科技有限公司 一种抗心衰药lcz696的制备方法
KR20200117037A (ko) * 2015-06-12 2020-10-13 테바 파마슈티컬스 인터내셔널 게엠베하 삼나트륨 발사르탄:사쿠비트릴의 고체 형태
WO2016203500A2 (en) 2015-06-19 2016-12-22 Actavis Group Ptc Ehf. Preparation of sacubitril or salt thereof and novel intermediates in the preparation of sacubitril
SI3317248T1 (sl) 2015-07-02 2021-01-29 Novartis Ag Sakubitril kalcijeve soli
WO2017006254A1 (en) 2015-07-08 2017-01-12 Novartis Ag Drug combination comprising an angiotensin ii receptor antagonist, a neutral endopeptidase inhibitor and a mineralcorticoid receptor antagonist
WO2017009784A1 (en) 2015-07-14 2017-01-19 Cadila Healthcare Limited Solid state forms of trisodium salt of valsartan/sacubitril complex and sacubitril
WO2017012600A1 (en) 2015-07-20 2017-01-26 Zentiva, K.S. A pharmaceutical composition containing valsartan and sacubitril and methods for preparation and stabilization thereof
JP6849618B2 (ja) 2015-07-23 2021-03-24 バイエル・ファルマ・アクティエンゲゼルシャフト 中性エンドペプチダーゼの阻害剤（ＮＥＰ阻害剤）および／またはアンジオテンシンＩＩ拮抗薬と組み合わせた可溶性グアニル酸シクラーゼ（ｓＧＣ）の刺激薬および／または活性化薬ならびにその使用
WO2017029261A1 (de) * 2015-08-19 2017-02-23 Bayer Pharma Aktiengesellschaft Kombinationspräparat umfassend finerenone und einen nep-inhibitor (sacubitril)
WO2017033128A1 (en) 2015-08-25 2017-03-02 Novartis Ag Biphenyl-substitued 4-amino-butyric acid derivatives and their use in the synthesis of nep inhibitors
JP6598985B2 (ja) 2015-08-28 2019-10-30 ノバルティス アーゲー 新規の使用
WO2017051326A1 (en) 2015-09-23 2017-03-30 Novartis Ag New processes and intermediates useful in synthesis of nep inhibitors
WO2017072636A1 (en) 2015-10-29 2017-05-04 Cadila Healthcare Limited Pharmaceutical synergistic combination
US10377697B2 (en) 2015-12-10 2019-08-13 Novartis Ag Process and intermediates
EP3386945A1 (en) * 2015-12-11 2018-10-17 Zentiva, K.S. Solid forms of (2r,4s)-5-(biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2- -methylpentanoic acid ethyl ester, its salts and a preparation method
CN106977417A (zh) * 2016-01-15 2017-07-25 常州方楠医药技术有限公司 一种沙库比曲钠盐的晶型及其制备方法
KR20180103940A (ko) 2016-02-03 2018-09-19 노파르티스 아게 유기 화합물의 갈레닉(Galenic) 제제
KR20180114225A (ko) 2016-03-08 2018-10-17 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 (2s,4r)-5-(5'-클로로-2'-플루오로-[1,1'-비페닐]-4-일)-2-(에톡시메틸)-4-(3-히드록시이속사졸-5-카르복사미도)-2-메틸펜탄산 결정 및 그 용도
US10682354B2 (en) 2016-03-28 2020-06-16 Intra-Cellular Therapies, Inc. Compositions and methods
CN105753733B (zh) * 2016-04-15 2019-06-18 苏州晶云药物科技股份有限公司 Ahu377的晶型及其制备方法与用途
CN105820064A (zh) * 2016-04-18 2016-08-03 浙江天宇药业股份有限公司 一种联苯基丙氨醇衍生物的合成方法及中间体
WO2017191620A1 (en) * 2016-05-06 2017-11-09 Sun Pharmaceutical Industries Limited A crystalline form of a salt of sacubitril and a process of its preparation
US20190256454A1 (en) 2016-07-05 2019-08-22 Novartis Ag New process for early sacubitril intermediates
CN107602399B (zh) * 2016-07-11 2020-09-25 江西东邦药业有限公司 一种脑啡肽酶抑制剂中间体的制备方法
WO2018033866A1 (en) 2016-08-17 2018-02-22 Novartis Ag New processes and intermediates for nep inhibitor synthesis
CN106318988B (zh) * 2016-08-23 2020-11-03 迪嘉药业集团有限公司 一种lcz696关键中间体的制备方法
US10683260B2 (en) 2016-09-07 2020-06-16 Nanjing Noratech Pharmaceuticals Co., Ltd. Crystalline form of sacubitril sodium salt
CN106478437A (zh) * 2016-09-27 2017-03-08 南通常佑药业科技有限公司 一种γ‑氨基戊酸酯衍生物的制备方法
CN106496055A (zh) * 2016-10-09 2017-03-15 杭州科巢生物科技有限公司 一种抗心衰新药的关键组分沙库比曲的新合成方法
WO2018069833A1 (en) * 2016-10-10 2018-04-19 Laurus Labs Limited Stable amorphous form of sacubitril valsartan trisodium complex and processes for preparation thereof
KR20190077467A (ko) 2016-10-28 2019-07-03 바이오콘 리미티드 비정질 삼나트륨 사쿠비트릴 발사르탄 및 이의 제조방법
EP3558930B1 (en) 2016-12-23 2021-05-26 Novartis AG New process for early sacubitril intermediates
WO2018153895A1 (de) 2017-02-22 2018-08-30 Bayer Pharma Aktiengesellschaft Selektive partielle adenosin a1 rezeptor-agonisten in kombination mit einem inhibitor der neutralen endopeptidase und/oder einem angiotensin ii rezeptor-antagonisten
CN106831473B (zh) * 2017-02-22 2019-07-16 江西瑞雅药业有限公司 3-酰胺基-4-(2’-烷氧基-4-联苯基)丁酸衍生物及其制备方法、药物组合物
WO2018178295A1 (en) 2017-03-31 2018-10-04 Alfred E. Tiefenbacher (Gmbh & Co. Kg) Stable hot-melt extrudate containing valsartan and sacubitril
WO2019020706A1 (en) 2017-07-28 2019-01-31 Synthon B.V. PHARMACEUTICAL COMPOSITION COMPRISING SACUBITRIL AND VALSARTAN
EP3694493A1 (en) 2017-10-13 2020-08-19 Alfred E. Tiefenbacher (GmbH & Co. KG) Tablet containing valsartan and sacubitril
WO2019127994A1 (zh) * 2017-12-27 2019-07-04 浙江天宇药业股份有限公司 一种沙库比曲钠盐、沙库比曲游离酸与乙酸的共晶物、其晶型、晶型的制备方法及用途
US11839614B2 (en) 2018-01-31 2023-12-12 Intra-Cellular Therapies, Inc. Methods for treating or mitigating cardiotoxicity characterized by inhibition of adenosine A2 signaling and/or adenosine A2 receptor expression
UY38072A (es) 2018-02-07 2019-10-01 Novartis Ag Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
GB201810326D0 (en) * 2018-06-22 2018-08-08 Johnson Matthey Plc Crystalline form of sacubitril, its preparation and use
WO2020039386A1 (en) 2018-08-23 2020-02-27 Novartis Ag New pharmaceutical use for the treatment of heart failure
WO2020039394A1 (en) 2018-08-24 2020-02-27 Novartis Ag New drug combinations
CN109503404A (zh) * 2018-12-28 2019-03-22 凯瑞斯德生化(苏州)有限公司 一种lcz-696关键中间体的制备方法
CN110128298B (zh) * 2019-06-13 2021-08-03 南京一心和医药科技有限公司 一种沙库巴曲中间体的合成方法
CN113135836A (zh) * 2020-01-20 2021-07-20 鲁南制药集团股份有限公司 一种沙库巴曲钙盐的制备方法
CN111253425B (zh) * 2020-02-21 2022-04-29 常州南京大学高新技术研究院 一种1,3-双[2-(3,4-环氧环己基)乙基]四甲基二硅氧烷的合成方法
JP7064527B2 (ja) * 2020-05-01 2022-05-10 ノバルティス アーゲー サクビトリルカルシウム塩
KR20220012821A (ko) 2020-07-23 2022-02-04 주식회사 종근당 이중 작용 복합 화합물의 결정형 및 이의 제조방법
CN112661671B (zh) * 2020-12-22 2022-04-22 江苏阿尔法药业股份有限公司 一种沙库巴曲中间体的制备方法
WO2022224274A1 (en) 2021-04-20 2022-10-27 Mylan Laboratories Limited Polymorphic forms of sacubitril-telmisartan (1:1)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE250531C (fi) *
US2543267A (en) * 1950-01-04 1951-02-27 Parke Davis & Co Hydroxyethyl-acylamidobiphenylyl ketones
US4206232A (en) * 1976-05-10 1980-06-03 E. R. Squibb & Sons, Inc. Relieving hypertension with carboxyalkylacylamino acids
FR2480747A1 (fr) * 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4721726A (en) * 1980-12-18 1988-01-26 Schering Corporation Substituted dipeptides as inhibitors of enkephalinases
US5096925A (en) * 1984-06-08 1992-03-17 Ciba-Geigy Corporation N-substituted butyramide derivatives
US4939261A (en) * 1984-06-08 1990-07-03 Ciba-Geigy Corporation N-substituted butyramide derivatives useful for treatment of conditions responsive to inhibition of enkephalinase
EP0225292A3 (en) * 1985-12-06 1988-11-30 Ciba-Geigy Ag Certain n-substituted butyramide derivatives
DD250531A1 (de) * 1985-12-23 1987-10-14 Adw Ddr Verfahren zur herstellung von malonylaminosaeure-p-nitrobenzylestern
CA1337400C (en) * 1987-06-08 1995-10-24 Norma G. Delaney Inhibitors of neutral endopeptidase
WO1989004821A1 (en) * 1987-11-25 1989-06-01 Pfizer Inc. N-(biphenylmethyl)-3-hydroxyglutaramic acid and derivatives as hypocholesterolemic agents
WO1991005555A2 (en) * 1989-10-13 1991-05-02 The Salk Institute Biotechnology/Industrial Associates, Inc. N-acyl peptide metalloendopeptidase inhibitors and methods of using same
US5217996A (en) * 1992-01-22 1993-06-08 Ciba-Geigy Corporation Biaryl substituted 4-amino-butyric acid amides

Also Published As

Publication number Publication date
CA2087652A1 (en) 1993-07-23
ZA93421B (en) 1993-07-22
NZ245716A (en) 1995-07-26
MX9300310A (es) 1993-07-01
AU3184293A (en) 1993-07-29
US5217996A (en) 1993-06-08
NO930193L (no) 1993-07-23
NO930193D0 (no) 1993-01-21
US5354892A (en) 1994-10-11
EP0555175A1 (en) 1993-08-11
FI930195A0 (fi) 1993-01-18
JPH05310664A (ja) 1993-11-22
IL104387A0 (en) 1993-05-13
AU666902B2 (en) 1996-02-29
TW228513B (fi) 1994-08-21
KR930016393A (ko) 1993-08-26
HUT63376A (en) 1993-08-30
HU9300166D0 (en) 1993-04-28

Similar Documents

Publication Publication Date Title
FI930195A0 (fi) Biarylsubstituerade 4-aminosmoersyraamider
FI921884A (fi) Fosfono/biarylsubstituerade dipeptidderivat
FI923280A (fi) Aminosubstituerade piperazinderivat
DK336089A (da) Biarylforbindelser
NO914666L (no) Fjerning av trialkylarsiner
FI931818A0 (fi) Foerfarande foer fenolextraktion ur fenoltjaera
NO934257D0 (no) Ekspanderbar pakning
MX9100998A (es) Novedosos inhibidores de escualen sintetasa
DE69328166D1 (de) Beseitigung von schmutzstoffen
FI930621A0 (fi) Bifenylsubstituerade kinolinderivat
DK33392D0 (da) Etgrebsblandingsarmatur
MX173974B (es) BLOQUE DE 45º
NO943167D0 (no) Modifisert TCF
DE69311862D1 (de) Kontinuierliche Dispergiervorrichtung
MX9102079A (es) Plemezcla de semduramicina
LV12073A (lv) Diizopinokamfenilhlorborana iegusanas panemiens
DK36193D0 (da) Fremgangsmaade
DE69218215D1 (de) Entfernung von schwefelwasserstoff
DK144292D0 (da) Forbedret fremgangsmaade
KR930026760U (ko) Tvcr의 개선된 구성
DE69417915D1 (de) Reinigung von uranhexafluorid
IT8847653A0 (it) Sizzante comprendente 5 - idroscomposizione farmaceutica anoressitrpofano
DE69121053D1 (de) Entschwefelung von triazolothiadiazinen
LV10073A (lv) Skidinataju absolutizesanas panemiens
DK86992D0 (da) Fremgangsmaade

Legal Events

Date Code Title Description
FD Application lapsed